company background image
1786

SciVision Biotech TWSE:1786 Stock Report

Last Price

NT$46.45

Market Cap

NT$3.0b

7D

1.4%

1Y

-7.2%

Updated

30 Sep, 2022

Data

Company Financials
1786 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health6/6
Dividends2/6

1786 Stock Overview

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan.

SciVision Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SciVision Biotech
Historical stock prices
Current Share PriceNT$46.45
52 Week HighNT$53.80
52 Week LowNT$38.80
Beta0.68
1 Month Change-9.81%
3 Month Change15.12%
1 Year Change-7.19%
3 Year Change-26.50%
5 Year Change29.54%
Change since IPO53.90%

Recent News & Updates

Shareholder Returns

1786TW Medical EquipmentTW Market
7D1.4%-5.6%-5.5%
1Y-7.2%-10.7%-19.3%

Return vs Industry: 1786 exceeded the TW Medical Equipment industry which returned -10.7% over the past year.

Return vs Market: 1786 exceeded the TW Market which returned -19.3% over the past year.

Price Volatility

Is 1786's price volatile compared to industry and market?
1786 volatility
1786 Average Weekly Movement6.0%
Medical Equipment Industry Average Movement5.5%
Market Average Movement5.2%
10% most volatile stocks in TW Market8.4%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 1786 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1786's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aTai Xian Hanhttps://www.scivision.com.tw

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.

SciVision Biotech Fundamentals Summary

How do SciVision Biotech's earnings and revenue compare to its market cap?
1786 fundamental statistics
Market CapNT$2.97b
Earnings (TTM)NT$112.08m
Revenue (TTM)NT$500.08m

27.4x

P/E Ratio

6.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1786 income statement (TTM)
RevenueNT$500.08m
Cost of RevenueNT$177.64m
Gross ProfitNT$322.45m
Other ExpensesNT$210.37m
EarningsNT$112.08m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.69
Gross Margin64.48%
Net Profit Margin22.41%
Debt/Equity Ratio21.1%

How did 1786 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

84%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 1786 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1786?

Other financial metrics that can be useful for relative valuation.

1786 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA17.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 1786's PE Ratio compare to its peers?

1786 PE Ratio vs Peers
The above table shows the PE ratio for 1786 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average22.8x
6612 ICARES Medicus
27.7xn/aNT$2.8b
4155 OK Biotech
20.7xn/aNT$2.3b
4129 United Orthopedic
24.2xn/aNT$2.4b
6747 Brighten Optix
19.2xn/aNT$4.6b
1786 SciVision Biotech
27.4xn/aNT$3.0b

Price-To-Earnings vs Peers: 1786 is expensive based on its Price-To-Earnings Ratio (27.4x) compared to the peer average (22.8x).


Price to Earnings Ratio vs Industry

How does 1786's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

Price-To-Earnings vs Industry: 1786 is expensive based on its Price-To-Earnings Ratio (27.4x) compared to the TW Medical Equipment industry average (18.6x)


Price to Earnings Ratio vs Fair Ratio

What is 1786's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1786 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1786's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 1786 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1786 (NT$46.45) is trading above our estimate of fair value (NT$31.78)

Significantly Below Fair Value: 1786 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is SciVision Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


2.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SciVision Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine SciVision Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has SciVision Biotech performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


23.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1786 has a large one-off gain of NT$30.5M impacting its June 30 2022 financial results.

Growing Profit Margin: 1786's current net profit margins (22.4%) are lower than last year (25.6%).


Past Earnings Growth Analysis

Earnings Trend: 1786 has become profitable over the past 5 years, growing earnings by 23.7% per year.

Accelerating Growth: 1786's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1786 had negative earnings growth (-10.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (19%).


Return on Equity

High ROE: 1786's Return on Equity (7.9%) is considered low.


Discover strong past performing companies

Financial Health

How is SciVision Biotech's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1786's short term assets (NT$711.5M) exceed its short term liabilities (NT$212.3M).

Long Term Liabilities: 1786's short term assets (NT$711.5M) exceed its long term liabilities (NT$380.9M).


Debt to Equity History and Analysis

Debt Level: 1786 has more cash than its total debt.

Reducing Debt: 1786's debt to equity ratio has reduced from 53.5% to 21.1% over the past 5 years.

Debt Coverage: 1786's debt is well covered by operating cash flow (32.5%).

Interest Coverage: 1786's interest payments on its debt are well covered by EBIT (29.3x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is SciVision Biotech current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


3.05%

Current Dividend Yield

Dividend Yield vs Market

SciVision Biotech Dividend Yield vs Market
How does SciVision Biotech dividend yield compare to the market?
SegmentDividend Yield
Company (SciVision Biotech)3.1%
Market Bottom 25% (TW)2.6%
Market Top 25% (TW)7.0%
Industry Average (Medical Equipment)4.0%
Analyst forecast in 3 Years (SciVision Biotech)n/a

Notable Dividend: 1786's dividend (3.05%) is higher than the bottom 25% of dividend payers in the TW market (2.57%).

High Dividend: 1786's dividend (3.05%) is low compared to the top 25% of dividend payers in the TW market (7.03%).


Stability and Growth of Payments

Stable Dividend: 1786 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 1786's dividend payments have increased, but the company has only paid a dividend for 7 years.


Earnings Payout to Shareholders

Earnings Coverage: At its current payout ratio (83.7%), 1786's payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (112.1%), 1786's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Tai Xian Han

no data

Tenure

Tai Xian Han serves as a General Manager of Scivision Biotech Inc and serves as its Director.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 1786?
Owner TypeNumber of SharesOwnership Percentage
Institutions56,7830.09%
General Public66,133,64299.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 1 shareholders own 0.017% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.017%
State Street Global Advisors, Inc.
11,000NT$511.0k0%no data

Company Information

SciVision Biotech Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: SciVision Biotech Inc.
  • Ticker: 1786
  • Exchange: TWSE
  • Founded: 2001
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: NT$2.965b
  • Shares outstanding: 66.19m
  • Website: https://www.scivision.com.tw

Location

  • SciVision Biotech Inc.
  • 1, South 1st Road
  • Cianjhen District
  • Kaohsiung
  • 806
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1786TWSE (Taiwan Stock Exchange)YesCommon StockTWTWDDec 2010

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.